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Abstract
Purpose To assess whether diabetes is a risk factor for
herpes zoster (HZ).
Methods We conducted a retrospective cohort study
using the Integrated Health Care Information Services
database, during the period 1997–2006. A type I diabetes
cohort, a type II diabetes cohort and two non-diabetic
cohorts matched for date of enrolment and duration of
follow-up were defined. HZ and diabetes were defined
using a combination of ICD-9 and prescription drug codes.
Individuals with immunosuppressive conditions or treat-
ments were excluded. Cox Proportional Hazards regression
analysis using a stepwise method with backward elimina-
tion was applied to estimate the hazard ratios (HR) of HZ,
including age, gender and co-morbidities as covariates.
Results The study population comprised 380,401 and
20,397 type II and type I diabetic subjects respectively, as
well as 1,521,604 and 81,588 matched controls. The
median ages were 55, 35, 33 and 29 years, respectively.
HZ incidence was 4.59, 2.13, 1.97, and 1.82 per 1,000
person-years, respectively. There was no evidence of an
impact of type I diabetes on the risk of HZ. Type II dia-
betes was associated with an increased risk for HZ in
subjects C65 (HR 3.12; 95 % CI 2.77–3.52, adjusted for
gender) and in subjects between 40 and 64 (HR 1.51; 95 %
CI 1.42–1.61) years of age. Cardiac disease and chronic
pulmonary disease were also risk factors (HR 1.92; 95 %
CI 1.73–2.13 and HR 1.52; 95 % CI 1.38–1.67) in non-
diabetic subjects.
Conclusions This study suggests that type II diabetes is
associated with an increased risk of developing HZ, which
was particularly high in adults 65 years and older and
moderately increased in adults under 65 years of age.
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Introduction
Herpes zoster (HZ) or ‘‘shingles’’ is a disease resulting
from the reactivation of latent varicella zoster virus (VZV).
About one million cases of HZ occur annually in the US
[1]. The most common complication is post-herpetic neu-
ralgia (PHN) in which neuropathic pain remains long after
the HZ lesions have healed and often persists for several
months. Herpes zoster ophthalmicus (HZO) accounts for
10–20 % of HZ cases and is more often associated with
chronic and detrimental sequelae, in comparison with other
dermatomal manifestations of HZ [2]. Rare visceral and
neurological complications such as encephalitis or myelitis
have also been reported [3].
The waning of virus-specific cell-mediated immunity
(CMI) is believed to be a major cause of VZV reactivation.
This can occur as part of the aging process or as a result of
medical conditions associated with immunosuppression
such as HIV infection, transplantation, cancer, and immune
mediated diseases [4–9]. At the population level, about
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two-thirds of HZ cases occur in adults 50 years and older
[10] and approximately 90 % of HZ cases occur among
otherwise immunocompetent individuals (of all ages)
without any identified immunosuppressive condition or
treatment [11, 12]. While the causes of HZ are imperfectly
understood, additional risk factors include mechanical
trauma and psychological stress, female gender, and white
race (compared to black race) [1, 13]. An association
between diabetes and HZ is supported by observations of
Okamoto et al. [14] who showed that subjects with diabetes
between 41 and 79 years had significantly lower cell
mediated immunity to varicella zoster virus than did
healthy individuals. Epidemiological studies investigating
the association between HZ and diabetes are few and have
yielded contradictory results, with studies suggesting that
diabetes is a risk factor for HZ [15–17] and others failing to
demonstrate a statistically significant association [5, 6, 18].
Most of these studies addressed multiple risk factors for
HZ, among which figured diabetes. Our objective was to
examine the association between HZ and type I and type II
diabetes in a large US insurance claim database.
Methods
Study design and data source
We conducted a retrospective matched cohort study using
the Integrated Health Care Information Services database
(IHCIS), a fully de-identified database that includes the
medical history of more than 74 million individuals from
46 health plans in the United States. The study period, 1
January 1997 to 25 May 2006, represents the 10 years
prior to the introduction of Zostavax, a vaccine to pre-
vent HZ in adults aged 60 years and older, in the United
States. Four study cohorts were defined: a type I diabetes
cohort, a type II diabetes cohort and two comparative
cohorts of non-diabetics. The diabetes type I and II
cohorts comprised all diabetic subjects in the database
with at least 12 months of contribution to the database
after the first diagnosis code for diabetes, excluding
individuals with a treatment or disorder causing immu-
nodeficiency (chemotherapy/radiation therapy, systemic
steroids, immunosuppressive drugs, organ transplants,
HIV, cancers, immunodeficiency disorders and autoim-
mune disease), renal disease (other than diabetic
nephropathy), hepatic disease, metabolic syndrome, and
individuals with a history of HZ before diagnosis of
diabetes. Four non-diabetic subjects per control cohort
were matched to each type I and II diabetic subject on the
date of entry (month and year) into the database and the
duration of follow-up (in months), applying the same
exclusion criteria as for the diabetic subjects.
Case definitions
Diabetic subjects were identified based on ICD-9 codes, as
described in the Appendix. Criteria were applied to dis-
tinguish between type I and type II diabetes for subjects
with no fifth digit in ICD-9 code: a subject with any oral
antidiabetic drugs would be classified as a type II diabetic
patient, a diabetic subject less than 20 years of age and on
insulin would be classified as a type I diabetic patient.
Subjects with no fifth digit in ICD-9 codes over 20 years of
age and on insulin only were excluded, as the classification
could not be made accurately.
A primary episode of HZ was defined by a first
appearance of a diagnostic ICD-9 code for HZ (053.x)
occurring 3 months or more after entry into the database
and before 25 May 2006. Codes 053.12 for post-herpetic
trigeminal neuralgia and 053.13 for post-herpetic poly-
neuropathy were excluded because of the increased
potential for these cases to represent sporadic long-term
follow-up for a prior HZ episode. Cases of HZ ophtalmicus
were identified through specific ICD-9 codes listed in the
Appendix.
Post-herpetic neuralgia was defined using the following
criteria: (1) the presence of an ICD-9 code for HZ fol-
lowed, within 3 months, by an ICD-9 code indicative of
PHN 053.12 or 053.13, or (2) the presence of an ICD-9
code for HZ followed by a PHN medication for more than
30 days starting within 30 days after the HZ diagnosis, or
(3) the presence of an ICD-9 code for HZ followed, within
3 months, by the appearance of an ICD-9 code for chronic
pain.
Co-morbidities and immunocompromising conditions
were identified through ICD-9 codes indicative of the
disease or a transplantation procedure (Appendix).
Selection of control groups
Type I and type II diabetic subjects were matched to four
non diabetic subjects on the date of entry (month and year)
into the database and the length of follow-up time (in
months). As for diabetic subjects, controls were excluded if
they had a disease or treatment causing immunodeficiency,
renal or hepatic disease, metabolic sydrome.
Statistical analysis
The follow-up period began with the index date, which was
defined as the date of the first diabetes-specific ICD-9 code
for individual diabetic subjects. This index date was also
assigned to matched non-diabetics. The follow-up period
for all cohorts continued until the first HZ event, the date of
introduction of the HZ vaccine ZostavaxTM (Merck & Co.,
Inc) in the United States (25 May 2006), or until lost-to-
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follow up, whichever came first. Incidence was calculated
as the number of events divided by the sum of the person-
time contributed by each qualified study participant in the
diabetic and control cohorts. Stratum specific rates, where
appropriate, and rate ratios comparing incidence rates
between diabetic and control cohort were computed. Log-
Rank tests were used to compare the two groups, with a
p value under 0.05 considered significant. Cox Proportional
Hazards regression analysis was applied to estimate the
hazard ratios (HR) of HZ associated with type I and type II
diabetes. These results were adjusted for age, gender and
other potential covariates identified through univariate
analyses. Age was categorized as \18, 18–29, 30–39,
40–49, 50–64 and C65 years. A stepwise method with
backward elimination applied to the full model was used to
select covariates to be included in the final model.
Covariates remained in the model only if the p value was
lower than 0.05. The proportional hazards assumption was
assessed using the goodness of fit testing approach with
p value significant at\0.05. Results from the multivariable
models were expressed as adjusted hazard ratios with 95 %
CIs.
Results
The study population comprised 380,401 and 20,397 type
II and type I diabetic subjects respectively, as well as
1,521,604 and 81,588 control subjects. Characteristics of
the population are described in Table 1. Subjects in the
type II diabetes cohort were older and included more males
than subjects in the three other cohorts, for which the age
distribution and sex ratio were similar.
Crude HZ incidence was 4.59, 2.13, 1.97, and 1.82 per
1,000 person-years (PY) in the type II and I diabetic and
matched cohorts, respectively. The age-specific incidence
of HZ is described in Table 2. In all cohorts, HZ incidence
increased with age. In both diabetic cohorts, HZ was more
frequent in women than in men. In the various cohorts, the
proportion of HZ cases with HZ ophtalmicus ranged
between 4–9 % and 2–7 % developed PHN. The incidence
of PHN was 0.19 (95 % CI 0.15–0.23) and 0.34 (95 % CI
0.27–0.43) per 1,000 PY in type II diabetics aged
50–64 years and older than 65 years, respectively and 0.12
(95 % CI 0.09–0.16) in the control cohorts for the same age
groups.
Type II diabetes was associated with an increased risk
for HZ, with age acting as an effect modifier (statistically
significant age-by-type II diabetes interaction,
p \ 0.0001). The HR of HZ associated with type II dia-
betes was 3.12 (95 % CI 2.77–3.52) in subjects C65 years
of age and 1.51 (95 % CI 1.42–1.61) in subjects between
40 and 64 years of age, adjusting for gender and co-
morbidities (Table 3). Cardiac disease and chronic pul-
monary disease were identified as other risk factors for HZ
(HR 1.92; 95 % CI 1.73–2.13 and HR 1.52; 95 % CI
1.38–1.67 in non-diabetic subjects) and modified the effect
of type II diabetes on the risk of HZ. Figure 1 illustrates
the HR of developing HZ associated with diabetes and
other co-morbidities compared with ‘‘healthy’’ subjects
(neither diabetic nor co-morbidities by age). Subjects
having multiple co-morbidities (COPD or coronary disease
in addition to type II diabetes) had higher risk than sub-
jects with a single condition but the total risk was lower
than the sum of each individual risk. The risks are not
additive.
Table 1 Characteristics of the
study population
Characteristics Type II
diabetes
Non-diabetics matched
with type II diabetes
Type I
diabetes
Non-diabetics matched
with type II diabetes
Number of subjects 380,401 1,521,604 20,397 81,588
Median age, years
(range)
55.0 (0–82) 33.0 (0–82) 35.0 (0–82) 29.0 (0–82)
Age category, n (%)
\18 years 5,056 (1.3) 481,366 (31.6) 4,753 (23.3) 27,570 (33.8)
18–29 years 11,951 (3.1) 208,422 (13.7) 3,414 (16.7) 13,237 (16.2)
30–39 years 34,272 (9.0) 217,176 (14.3) 3,938 (19.3) 12,431 (15.2)
40–49 years 75,326 (19.8) 233,131 (15.3) 3,092 (15.2) 12,145 (14.9)
50–64 years 182,863 (48.1) 219,050 (14.4) 3,165 (15.5) 10,329 (12.7)
C65 years 70,933 (18.7) 162,459 (10.7) 2,035 (10.0) 5,876 (7.2)
Gender ratio M/F, n (%)
F 156,802 (41.3) 741,357 (48.7) 9,613 (47.1) 39,709 (48.7)
M 223,599 (58.8) 780,247 (51.3) 10,784 (52.9) 41,879 (51.3)
Follow-up time (months)
Mean ± SD 44.5 ± 20.1 44.5 ± 20.1 39.3 ± 21.4 39.3 ± 21.4
Median 44.0 44.0 35.0 35.0
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There was no evidence of an impact of type I diabetes
on the risk of HZ. The HR for HZ among type I diabetic
subjects was in the range 0.70–1.94 across age groups.
Discussion
There is contradictory evidence on the potential risk that
type I and type II diabetes may pose for the occurrence of
HZ. This study suggests that type II diabetes is associated
with an increased risk of developing HZ. The magnitude of
the risk associated to type II diabetes is conditioned by the
age of the individual and the presence of comorbidities: it
was highest in type II diabetics 65 years or older, who had
a three-fold increased risk of developing HZ compared to
non-diabetics. Type II diabetics between 40 and 64 were
50 % more likely to develop HZ compared with non-dia-
betics of the same age. Type I diabetes was not identified as
an independent risk factor for HZ.
These findings compare with another retrospective study
conducted in Israel [15] which found that diabetes was
associated with an increased odds of HZ (OR = 1.53;
95 % CI 1.44–1.62), comparing 22,294 HZ cases with
88,895 controls. Another recent primary health care data-
base analysis in Spain concluded that diabetics
(n = 26,793) presented an adjusted relative risk of 2.1
(95 % CI 1.9–2.4) of developing HZ compared to non-
diabetics [17]. These studies, as ours, were designed to
assess the association between HZ and diabetes. However,
our study included a larger population of diabetics and
differentiated type I and type II diabetics. In the US Market
Scan database (subjects from 20 to 64 years of age), the
Table 2 Herpes zoster incidence (cases/1,000 person-years) in the type I and II diabetics cohorts and control groups, stratified by gender and age
Disease Group Type II diabetes
(n = 380,401)
Non-diabetics matched with
type II diabetes (n = 1,521,604)
Type I diabetes
(n = 20,397)
Non-diabetics matched with
type I diabetes (n = 81,588)
Herpes zoster Total 4.59 (4.45–4.74)
n = 380,401
1.97 (1.92–2.02)
n = 1,521,604
2.13 (1.72–2.6)
n = 20,397
1.82 (1.64–2.01)
n = 81,588
Gender
M 4.03 (3.86–4.21)
n = 223,599
1.77 (1.71–1.83)
n = 780,247
1.94 (1.42–2.6)
n = 10,784
1.68 (1.45–1.95)
n = 41,879
F 5.4 (5.16–5.65)
n = 156,802
2.18 (2.11–2.25)
n = 741,357
2.34 (1.72–3.1)
n = 9,613
1.96 (1.7–2.25)
n = 39,709
Age group (years)
\18 1.02 (0.53–1.78)
n = 5,056
1.13 (1.07–1.19)
n = 481,366
1.03 (0.51–1.84)
n = 4,753
1.11 (0.88–1.38)
n = 27,570
18–29 2.93 (2.31–3.68)
n = 11,951
1.48 (1.37–1.59)
n = 208,422
1.49 (0.71–2.74)
n = 3,414
1.4 (1.03–1.86)
n = 13,237
30–39 2.22 (1.9–2.57)
n = 34,272
2.09 (1.97–2.22)
n = 217,176
2.08 (1.21–3.33)
n = 3,938
1.78 (1.36–2.29)
n = 12,431
40–49 3.17 (2.91–3.44)
n = 75,326
2.34 (2.21–2.47)
n = 233,131
3.02 (1.85–4.67)
n = 3,092
2.45 (1.94–3.06)
n = 12,145
50–64 5.01 (4.8–5.23)
n = 182,863
3.55 (3.39–3.72)
n = 219,050
3.2 (2.01–4.85)
n = 3,165
3.39 (2.71–4.19)
n = 10,329
C65 6.54 (6.17–6.94)
n = 70,933
2.4 (2.24–2.57)
n = 162,459
2.77 (1.48–4.74)
n = 2,035
2.38 (1.6–3.39)
n = 5,876
Table 3 Hazard ratio for herpes zoster event associated with type II
diabetes, cardiac disease, COPD and gender
Effect HR 95 % CI
Diabetes Type II in
Subjects age 18–29, age 40–49, and age 50–64
(ref. non type II diabetics, same age)
1.51 1.41 1.61
Subjects age \18 (ref. non type II diabetics,
same age)
0.78 0.43 1.42
Subject at age 30–39 (ref. non type II diabetics,
same age)
1.01 0.84 1.21
Subjects at age C65 (ref. non type II diabetics,
same age)
3.12 2.77 3.52
Cardiac disease subjects (ref. non type II
diabetics with cardiac disease)
0.91 0.8 1.04
COPD subjects (ref. non type II diabetics with
COPD)
1.14 0.98 1.33
Cardiac disease in non-diabetic subjects (ref. non
cardiac disease, non-diabetic)
1.92 1.73 2.13
COPD in non-diabetic subjects (ref. non COPD,
non diabetic)
1.52 1.38 1.67
Gender: male (ref. female) 0.78 0.75 0.82
Note: because of a statistically significant interaction between the
effect of diabetes type II and age and other comorbidity, HR were
calculated per age class and comorbidity status
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OR associated with diabetes was 1.06 (1.03–1.09), diabetes
being considered as a risk factor among eight other chronic
conditions [16]; this study did not include adults over
65 years of age, in whom we identified the strongest effect
of type II diabetes on the risk of HZ. Some studies did not
find any link between HZ and diabetes. Of note, they were
not specifically designed to address this question or were
conducted in populations with specific co-comorbidities [6,
19]. In a prospective matched case–control study Lasserre
et al. [18] found that diabetes was associated with HZ in
the univariate analysis, but the association was not signif-
icant in the multivariate analysis. Not taking into account
an interaction between age and type II diabetes may result
in underestimating the effect of type II diabetes in the
elderly.
Data from Japan comparing 63 patients with diabetes
and 67 healthy volunteers showed that patients with dia-
betes had significantly lower CMI to VZV than did healthy
individuals [14]. CMI is critical in controlling reactivation
of the VZV virus, this may explain the increased risk for
developing HZ observed in diabetics. This study did not
observe a difference of anti-VZV antibody titer in patients
with diabetes and healthy volunteers.
Our study also highlighted that other chronic conditions
such as cardiac diseases and chronic pulmonary diseases
are risk factors for HZ development. A cohort study using
data from the Taiwan Longitudinal Health Insurance
Database has also suggested a potential association
between chronic obstructive pulmonary disease and HZ
[20], with an adjusted HR of 1.68 (95 % CI 1.45–1.95), the
risk of HZ being greatest for patients with COPD using oral
steroids. Similarly, Joesoef et al. showed evidence of
COPD as a risk factor for HZ (adjusted OR 1.35, 95 % CI
1.23–1.47). The same study found coronary diseases to
modestly increase the risk of HZ (1.17, 95 % CI
1.11–1.22). Our results show that subjects having multiple
co-morbidities (COPD or coronary disease in addition to
type II diabetes) had higher risk than subjects with a single
condition but the total risk was lower than the sum of each
individual risk.
We also observed a higher incidence of HZ among
women than men. This has been described elsewhere. The
Shingles Prevention Study indicated that the incidence of
confirmed HZ cases in a cohort of immunocompetent
persons aged [60 years was 11 % higher among women
(11.8 vs 10.7 cases per 1,000 PY in women and men,
respectively) [21]. A review of HZ epidemiology in Europe
showed that incidence rates are systematically higher
among women than men (male/female ratio around 1.4),
and this difference increased with age [22]. Other studies in
North America have also shown an age standardized excess
of zoster among women [23]. The reason is not known.
One hypothesis is that women might be more likely to seek
medical advice, thereby causing a higher reporting rate.
However, this difference has been observed in a phase III
clinical trial where active case finding has been imple-
mented, with similar procedures for men and women.
Another potential explanation is the role of a biological
mechanism by which women would be more susceptible to
VZV reactivation.
Risk factors for HZ are still imperfectly understood. The
role of aging and underlying immunocompromising con-
ditions is well recognized. However, the impact of chronic
diseases is still unclear. Multiple chronic conditions have
been identified as potential risk factors for HZ, including
lung disease and COPD [6, 19, 20], liver disease [6], renal
failure [6], depression [16, 18, 24], coronary diseases,
hyperlipidemia, osteoarthritis, hypothyroism [16]. For
many of those, the population-attributable fraction, i.e. the
excess of HZ cases that could be attributable to the pre-
sence of the conditions, seems modest, ranging between
0.24 and 2.89 %. Further studies would be needed to
confirm their association with HZ and explain the biolog-
ical mechanism involved. This multiplicity of risk factors
also questions the prevention messages around vaccination
against HZ, which may need to target not only older adults
Fig. 1 Hazard ratio for
developing herpes zoster
associated with type II diabetes
and co-morbidities (reference
‘‘healthy’’ subjects, without
diabetes nor co-morbidity), by
subject age
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but also populations with co-morbidities which have a
substantial impact on the risk of HZ.
In our study, between 2 and 7 % of HZ cases developed
PHN, which was defined using an algorithm combining
ICD-9 codes and prescription drugs. In prospective studies,
PHN is reported among 10–20 % of HZ cases, its fre-
quency and duration increasing with older age [10]. There
is no standard definition of PHN and the proportion of
patients reported to develop PHN varies across studies
depending on the definition used and the characteristics
(age in particular) of the study population. Identifying PHN
in administrative databases is further complicated by the
fact that the ICD-9 classification did not include specific
PHN codes. Recent database studies reported proportions
of HZ patients with PHN ranging from 4.3 % [25] in the
US Market Scan Research Database to 6.2 % in primary-
care database and national hospital-discharge records
covering four regions in Italy [11], which is in the range of
our observations. Case definitions combining ICD-9 codes
and medications generally lack sensitivity to capture PHN
cases in administrative databases. A definition with high
sensitivity is usually detrimental to the specificity [26].
Our study presents several limitations. We could not
assess the validity of the diagnoses from this insurance
claims database. Identification of HZ cases through ICD-9
codes is generally assumed to be a valid method, with a
high positive predictive value (PPV) generally ranging
between 84–100 % in several health care plans [5, 15, 26].
In one study conducted in Veterans Health Administration
Decision Support System [27], only 56 % of HZ episodes
identified through ICD-9 codes were confirmed as acute
HZ after review of the medical records, illustrating that
ICD-9 codes may be frequently erroneous and that the PPV
may vary by data source. In addition, extensive work on
algorithms for PHN detection at 3 months post-HZ onset
showed that high sensitivity (80 % or more) is detrimental
to the PPV (\41 %) and that the algorithm with the highest
PPV (52 %) missed more than half of PHN cases (sensi-
tivity of 45 %) [26]. There is also a risk that misclassifi-
cation may have occurred for diabetes and comorbidities.
The number of type II diabetic subjects \18 years of age
seemed substantial when considering the epidemiology of
type II diabetes and suggests potential classification bias.
However, the impact on the study results is likely small, the
number of subjects being limited.
There is a major difference of age distribution between
the type II diabetic cohort and its control cohort. We did
not select age as a matching factor, as it would have pre-
vented us from analyzing the impact of age on the risk of
HZ. We have therefore focused our analysis on age-strat-
ified comparisons. The incidence of HZ in all age groups
appears to be lower than what is usually reported in the
literature for similar age groups; i.e. around 4.2–4.6 per
1,000 PY in the 50–59, 6–6.9 in the 60–69 and 8.6–9.5 in
the 70–79 [12, 28]. This is particularly noticeable for the
age group C65 years of age in the control cohort for type II
diabetics. In the study, we excluded immunocompromised
individuals at increased risk of HZ. Restricting the study
population to immunocompetent individuals, we observed
HZ incidences that are logically lower than in the overall
population. Previous studies have shown that about
8–12 % of individuals with HZ are immunocompromised
[11, 12]. Thus, excluding those individuals from the study
does not seem to fully explain why the HZ incidence rates
observed are lower than in other settings. The IHCIS
database includes data from commercially insured indi-
vidual for reimbursement purposes, and coding biases may
have occurred. It is possible that the incidence of HZ has
been underestimated in the diabetic cohorts and control
groups, although we could not identify if the diabetic
cohorts were affected in a different extent.
Due to a restricted number of diabetic subjects with
documented HBA1c recorded results, the impact of good
versus poor glycemic control was not assessed. In the case–
control study performed using the Maccabi Healthcare
Services databases, Heymann et al. had found that among
individuals with documented diabetes, individuals under 45
with high levels ([8 %) of HbA1c prior to the HZ episode
had a significantly increased risk of HZ compared to
patients with Hba1c if \5 %. No similar differences had
been observed in older ages.
Conclusion
This study suggests that type II diabetes is associated with
a moderately increased risk of developing HZ in individ-
uals between 18 and 64 years of age. A higher risk increase
was associated with type II diabetics in adults 65 years and
older.
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